CK Life Sciences and CK Hutchison completed the $11m investment in Pharus from Quark Biosciences.

CK Life Sciences, a company engaged in research and development, commercialization, marketing and sale of biotechnology products, and CK Hutchison, a Hong Kong-based and Cayman Islands-registered multinational conglomerate corporation, completed the $11m investment in Pharus, a greenfield business in Taiwan focusing on the research, development and commercialisation of molecular diagnostics for the early detection of cancer, from Quark Biosciences, a biotechnology company. The deal has the potential for an attractive return and capital appreciation and CK Life Sciences is also keeping an eye on different companies, such as pharmaceuticals and testing, to assess the prospects of each firm for future investment